Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEOMOLOGY MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 PIPELINE ANALYSIS
13.1 CLINICAL TRIALS AND PHASE ANALYSIS
13.2 DRUG THERAPY PIPELINE
13.3 PHASE III CANDIDATES
13.4 PHASE II CANDIDATES
13.5 PHASE I CANDIDATES
13.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR POST-ACUTE MYOCARDIAL INFARCTION MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR POST-ACUTE MYOCARDIAL INFARCTION MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR POST-ACUTE MYOCARDIAL INFARCTION MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR POST-ACUTE MYOCARDIAL INFARCTION MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR POST-ACUTE MYOCARDIAL INFARCTION MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
14 REIMBURSEMENT FRAMEWORK
15 OPPUTUNITY MAP ANALYSIS
16 VALUE CHAIN ANALYSIS
17 HEALTHCARE ECONOMY
17.1 HEALTHCARE EXPENDITURE
17.2 CAPITAL EXPENDITURE
17.3 CAPEX TRENDS
17.4 CAPEX ALLOCATION
17.5 FUNDING SOURCES
17.6 INDUSTRY BENCHMARKS
17.7 GDP RATION IN OVERALL GDP
17.8 HEALTHCARE SYSTEM STRUCTURE
17.9 GOVERNMENT POLICIES
17.1 ECONOMIC DEVELOPMENT
18 GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET, BY DIAGNOSIS AND TREATMENT
18.1 OVERVIEW
18.2 DIAGNOSIS
18.2.1 ELECTROCARDIOGRAM (ECG)
18.2.2 BLOOD TESTS
18.2.2.1. TROPONIN
18.2.2.2. CK-MB
18.2.2.3. OTHERS
18.2.3 IMAGING TEST
18.2.3.1. ECHOCARDIOGRAPHY
18.2.3.2. CORONARY ANGIOGRAPHY
18.2.3.3. OTHERS
18.2.4 OTHERS
18.3 TREATMENT
18.3.1 MEDICATIONS
18.3.1.1. BY TYPE
18.3.1.1.1. MARKETED MEDICATION
18.3.1.1.1.1 BY DRUG CLASS
18.3.1.1.1.1.1. ANTIPLATELET AGENTS
A. ASPIRIN
I. BY DRUGS
II. ASCRIPTIN
III. BAYER ASPIRIN
IV. ASPIRTAB
V. ECOTRIN
VI. DURLAZA
VII. BY STRENGTH
VIII. 81MG
IX. 325MG
X. 500MG
XI. OTHERS
B. CLOPIDOGREL
I. BY DRUGS
II. PLAVIX
III. OTHERS
IV. BY STRENGTH
V. 75MG
VI. 300MG
C. TICAGRELOR
I. BY DRUG
II. BRILINTA
III. OTHERS
IV. BY STRENGTH
V. 60MG
VI. 90MG
D. PRASUGREL
I. BY DRUGS
II. EFFIENT
III. OTHERS
IV. BY STRENGTH
V. 5MG
VI. 10MG
E. VORAPAXAR
I. BY DRUGS
II. ZONTIVITY
III. OTHERS
18.3.1.1.1.1.2. ANTITHROMBOTIC AGENTS
A. BIVALIRUDIN
I. BY DRUGS
II. ANGIOMAX
III. ANGIOMAX RTU
IV. OTHERS
V. BY STRENGTH
VI. 5MG/ML
VII. 250MG/VIAL
B. HEPARIN
I. BY DRUGS
II. LOCK SOLUTION
III. INJECTIBLE SOLUTION
IV. BY STRENGTH
V. 1UNIT/ML
VI. 2UNITS/ML
VII. 10UNITS/ML
VIII. 100UNITS/ML
IX. OTHERS
C. ENOXAPARIN
I. BY DRUGS
II. LOVENOX
III. OTHERS
IV. BY STRENGTH
V. 30MG/0.3ML
VI. 40MG/0.4ML
VII. 60MG/0.6ML
VIII. BY DOSAGE
IX. MULTIDOSE VIAL
X. PREFILLED SYRINGES
D. DALTEPARIN
I. BY DRUGS
II. FRAGMIN
III. OTHERS
IV. BY STRENGTH
V. 2,500 IU/0.2 ML
VI. 5,000 IU/0.2 ML
VII. 7,500 IU/0.3 ML
VIII. OTHERS
18.3.1.1.1.1.3. GLYCOPROTEIN IIB/IIIA INHIBITORS
A. ABCIXIMAB
I. BY DRUGS
II. REOPRO
III. OTHERS
B. TIROFIBAN
I. BY DRUGS
II. AGGRASTAT
III. OTHERS
IV. BY STRENGTH
V. 5MG/100ML
VI. 12.5MG/250ML
C. EPTIFIBATIDE
I. BY DRUGS
II. INTEGRILIN
III. OTHERS
IV. BY STRENGTH
V. 2MG/ML
VI. 0.75MG/ML
18.3.1.1.1.1.4. VASODILATORS
A. NITROGLYCERIN IV
I. BY DRUG
II. GLYCERYL TRINITRATE IV
III. IV NITROGLYCERIN
IV. BY STRENGTH
V. 25MG/250ML
VI. 50MG/250ML
VII. OTHERS
B. OTHERS
18.3.1.1.1.1.5. BETA-ADRENERGIC BLOCKERS
A. METOPROLOL
I. BY DRUGS
II. LOPRESSOR
III. TOPROL XL
IV. BY STRENGTH
V. 25 MG
VI. 50 MG
VII. OTHERS
B. ESMOLOL
I. BY DRUGS
II. BREVIBLOC
III. OTHERS
IV. BY STRENGTH
V. 2G/100ML
VI. 2.5G/250ML
C. ATENOLOL
I. BY DRUGS
II. TENORMIN
III. OTHERS
IV. BY STRENGTH
V. 25MG
VI. 50MG
VII. 100MG
18.3.1.1.1.1.6. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
A. BY DRUG
I. CAPTOPRIL
II. ENALAPRIL
III. QUINAPRIL
IV. LISINOPRIL
B. BY STRENGTH
I. 25MG
II. 50MG
III. OTHERS
18.3.1.1.1.1.7. ANGIOTENSIN-RECEPTOR BLOCKERS
A. BY DRUGS
I. IRBESARTAN
II. CANDESARTAN
III. VALSARTAN
IV. AZILSARTAN
V. EPROSARTAN MESYLATE
VI. LOSARTAN
B. BY STRENGTH
I. 75MG
II. 150MG
III. OTHERS
18.3.1.1.1.1.8. THROMBOLYTICS
A. BY DRUGS
I. ALTEPLASE, T-PA
II. TENECTEPLASE
III. OTHERS
B. BY STRENGTH
I. 2MG
II. 50MG
18.3.1.1.1.1.9. ANALGESICS
A. BY DRUGS
I. MORPHINE SULFATE
II. OTHERS
B. BY STRENGTH
I. 15 MG
II. 30MG
III. OTHERS
18.3.1.1.1.1.10. PCSK9 INHIBITORS
A. BY DRUGS
I. EVOLOCUMAB
II. ALIROCUMAB
III. OTHERS
B. BY STRENGTH
I. 75MG/ML
II. 150MG/ML
III. OTHERS
18.3.1.1.1.1.11. STATIN THERAPY
A. BY DRUGS
I. ATORVASTATIN
II. STATIX
III. ATOREC
IV. LIPVAS
V. XTOR
VI. FLUVASTATIN
VII. LESCOL
VIII. LESCOL XL
IX. OTHERS
X. LOVASTATIN
XI. AZTATIN
XII. FAVOLIP
XIII. LESTRIC
XIV. LIPISTAT
XV. OTHERS
XVI. ROSUVASTATIN
XVII. CRESTOR
XVIII. EZALLOR SPRINKLE
XIX. OTHERS
XX. SIMVASTATIN
XXI. ZOCOR
XXII. FLILIPID
XXIII. VYTORIN
XXIV. PITAVASTATIN
XXV. LIVALO
XXVI. ZYPITAMAG
XXVII. OTHERS
B. BY STRENGTH
I. 10 MG
II. 20 MG
III. 40 MG
18.3.1.1.1.1.12. OTHERS
18.3.1.1.2. PIPELINE MEDICATION
18.3.1.1.2.1 RH001
18.3.1.1.2.2 SELATOGREL
18.3.1.1.2.3 KAND567
18.3.1.1.2.4 TBPCB201
18.3.1.1.2.5 MPC-25-IC
18.3.1.1.2.6 FDY-5301
18.3.1.1.2.7 RTP-026
18.3.1.1.2.8 ZALUNFIBAN
18.3.1.1.2.9 OTHERS
18.3.1.2. BY DRUG TYPE
18.3.1.2.1. BRANDED
18.3.1.2.1.1 DURLAZA
18.3.1.2.1.2 PLAVIX
18.3.1.2.1.3 BRILINTA
18.3.1.2.1.4 EFFIENT
18.3.1.2.1.5 OTHERS
18.3.1.2.2. GENERICS
18.3.1.3. BY ROUTE OF ADMINISTRATION
18.3.1.3.1. ORAL
18.3.1.3.1.1 TABLET
18.3.1.3.1.2 CAPSULE
18.3.1.3.1.3 OTHERS
18.3.1.3.2. PARENTERAL
18.3.1.3.2.1 INTRAVENEOUS
18.3.1.3.2.2 SUBCUTANEOUS
18.3.1.3.2.3 OTHERS
18.3.1.3.3. OTHERS
18.3.1.4. BY DISTRIBUTION CHANNEL
18.3.1.4.1. DIRECT TENDER
18.3.1.4.2. RETAIL SALES
18.3.1.4.2.1 ONLINE
18.3.1.4.2.1.1. COMPANY WEBSITE
18.3.1.4.2.1.2. E-STORES
18.3.1.4.2.1.3. OTHERS
18.3.1.4.2.2 OFFLINE
18.3.1.4.2.2.1. HOSPITAL PHARMACY
18.3.1.4.2.2.2. MEDICINE STORES
18.3.1.4.2.2.3. OTHERS
18.3.1.4.3. OTHERS
18.3.2 SURGICAL TREATMENT
18.3.2.1. CORONARY ARTERY BYPASS GRAFTING (CABG)
18.3.2.2. ANGIOPLASTY & STENTING
18.4 OTHERS
19 GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET, BY AGE GROUP
19.1 OVERVIEW
19.2 BELOW 30 YEARS
19.3 30 TO 50 YEARS
19.4 ABOVE 50 YEARS
20 GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET, BY GENDER
20.1 OVERVIEW
20.2 MALE
20.2.1 BELOW 30 YEARS
20.2.2 30 TO 50 YEARS
20.2.3 ABOVE 50 YEARS
20.3 FEMALE
20.3.1 BELOW 30 YEARS
20.3.2 30 TO 50 YEARS
20.3.3 ABOVE 50 YEARS
21 GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.2.1 BY TYPE
21.2.1.1. PUBLIC
21.2.1.2. PRIVATE
21.2.2 BY LEVEL
21.2.2.1. TIER 1
21.2.2.2. TIER 2
21.2.2.3. TIER 3
21.3 SPECIALTY CLINICS
21.3.1 PUBLIC
21.3.2 PRIVATE
21.4 HOME HEALTHCARE
21.5 CARDIAC RESEARCH INSTITUTES
21.6 AMBULATORY SURGICAL CENTRE
21.7 OTHERS
22 GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET, BY GEOGRAPHY
GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1 NORTH AMERICA
22.1.1 U.S.
22.1.2 CANADA
22.1.3 MEXICO
22.2 EUROPE
22.2.1 GERMANY
22.2.2 FRANCE
22.2.3 U.K.
22.2.4 IRELAND
22.2.5 ITALY
22.2.6 SPAIN
22.2.7 RUSSIA
22.2.8 TURKEY
22.2.9 NETHERLANDS
22.2.10 SWITZERLAND
22.2.11 REST OF EUROPE
22.3 ASIA-PACIFIC
22.3.1 JAPAN
22.3.2 CHINA
22.3.3 TAIWAN
22.3.4 SOUTH KOREA
22.3.5 INDIA
22.3.6 AUSTRALIA
22.3.7 SINGAPORE
22.3.8 THAILAND
22.3.9 MALAYSIA
22.3.10 INDONESIA
22.3.11 PHILIPPINES
22.3.12 REST OF ASIA-PACIFIC
22.4 SOUTH AMERICA
22.4.1 BRAZIL
22.4.2 ARGENTINA
22.4.3 REST OF SOUTH AMERICA
22.5 MIDDLE EAST AND AFRICA
22.5.1 SOUTH AFRICA
22.5.2 SAUDI ARABIA
22.5.3 UAE
22.5.4 EGYPT
22.5.5 ISRAEL
22.5.6 REST OF MIDDLE EAST AND AFRICA
22.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
23.6 MERGERS & ACQUISITIONS
23.7 NEW PRODUCT DEVELOPMENT & APPROVALS
23.8 EXPANSIONS
23.9 REGULATORY CHANGES
23.1 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL POST-ACUTE MYOCARDIAL INFARCTION MARKET, COMPANY PROFILE
24.1 MARKETED MANUFACTURE
24.1.1 PFIZER INC.
24.1.1.1. COMPANY OVERVIEW
24.1.1.2. REVENUE ANALYSIS
24.1.1.3. GEOGRAPHIC PRESENCE
24.1.1.4. PRODUCT PORTFOLIO
24.1.1.5. RECENT DEVELOPMENTS
24.1.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
24.1.2.1. COMPANY OVERVIEW
24.1.2.2. REVENUE ANALYSIS
24.1.2.3. GEOGRAPHIC PRESENCE
24.1.2.4. PRODUCT PORTFOLIO
24.1.2.5. RECENT DEVELOPMENTS
24.1.3 SANDOZ GMBH (MARKETING AUTHORISATION HOLDER -NOVARTIS AG)
24.1.3.1. COMPANY OVERVIEW
24.1.3.2. REVENUE ANALYSIS
24.1.3.3. GEOGRAPHIC PRESENCE
24.1.3.4. PRODUCT PORTFOLIO
24.1.3.5. RECENT DEVELOPMENTS
24.1.4 ORGANON GROUP OF COMPANIES
24.1.4.1. COMPANY OVERVIEW
24.1.4.2. REVENUE ANALYSIS
24.1.4.3. GEOGRAPHIC PRESENCE
24.1.4.4. PRODUCT PORTFOLIO
24.1.4.5. RECENT DEVELOPEMENTS
24.1.5 MERCK SHARP & DOHME CORP (A SUBSIDIARY OF MERCK & CO., INC.)
24.1.5.1. COMPANY OVERVIEW
24.1.5.2. REVENUE ANALYSIS
24.1.5.3. GEOGRAPHIC PRESENCE
24.1.5.4. PRODUCT PORTFOLIO
24.1.5.5. RECENT DEVELOPEMENTS
24.1.6 VIATRIS INC.
24.1.6.1. COMPANY OVERVIEW
24.1.6.2. REVENUE ANALYSIS
24.1.6.3. GEOGRAPHIC PRESENCE
24.1.6.4. PRODUCT PORTFOLIO
24.1.6.5. RECENT DEVELOPEMENTS
24.1.7 NOVADOZ PHARMACEUTICALS
24.1.7.1. COMPANY OVERVIEW
24.1.7.2. REVENUE ANALYSIS
24.1.7.3. GEOGRAPHIC PRESENCE
24.1.7.4. PRODUCT PORTFOLIO
24.1.7.5. RECENT DEVELOPEMENTS
24.1.8 ASTRAZENECA
24.1.8.1. COMPANY OVERVIEW
24.1.8.2. REVENUE ANALYSIS
24.1.8.3. GEOGRAPHIC PRESENCE
24.1.8.4. PRODUCT PORTFOLIO
24.1.8.5. RECENT DEVELOPEMENTS
24.1.9 KOWA COMPANY, LTD.
24.1.9.1. COMPANY OVERVIEW
24.1.9.2. REVENUE ANALYSIS
24.1.9.3. GEOGRAPHIC PRESENCE
24.1.9.4. PRODUCT PORTFOLIO
24.1.9.5. RECENT DEVELOPMENTS
24.1.10 DR. REDDY'S LABORATORIES LIMITED
24.1.10.1. COMPANY OVERVIEW
24.1.10.2. REVENUE ANALYSIS
24.1.10.3. GEOGRAPHIC PRESENCE
24.1.10.4. PRODUCT PORTFOLIO
24.1.10.5. RECENT DEVELOPMENTS
24.1.11 GLENMARK PHARMACEUTICALS LTD .
24.1.11.1. COMPANY OVERVIEW
24.1.11.2. REVENUE ANALYSIS
24.1.11.3. GEOGRAPHIC PRESENCE
24.1.11.4. PRODUCT PORTFOLIO
24.1.11.5. RECENT DEVELOPMENTS
24.1.12 LUPIN
24.1.12.1. COMPANY OVERVIEW
24.1.12.2. REVENUE ANALYSIS
24.1.12.3. GEOGRAPHIC PRESENCE
24.1.12.4. PRODUCT PORTFOLIO
24.1.12.5. RECENT DEVELOPMENTS
24.1.13 ABBOTT
24.1.13.1. COMPANY OVERVIEW
24.1.13.2. REVENUE ANALYSIS
24.1.13.3. GEOGRAPHIC PRESENCE
24.1.13.4. PRODUCT PORTFOLIO
24.1.13.5. RECENT DEVELOPMENTS
24.1.14 BAYERS AG
24.1.14.1. COMPANY OVERVIEW
24.1.14.2. REVENUE ANALYSIS
24.1.14.3. GEOGRAPHIC PRESENCE
24.1.14.4. PRODUCT PORTFOLIO
24.1.14.5. RECENT DEVELOPMENTS
24.1.15 ZYDUS LIFESCIENCES LTD.
24.1.15.1. COMPANY OVERVIEW
24.1.15.2. REVENUE ANALYSIS
24.1.15.3. GEOGRAPHIC PRESENCE
24.1.15.4. PRODUCT PORTFOLIO
24.1.15.5. RECENT DEVELOPMENTS
24.1.16 TEVA PHARMACEUTICALS INDUSTRIES LTD.
24.1.16.1. COMPANY OVERVIEW
24.1.16.2. REVENUE ANALYSIS
24.1.16.3. GEOGRAPHIC PRESENCE
24.1.16.4. PRODUCT PORTFOLIO
24.1.16.5. RECENT DEVELOPMENTS
24.1.17 AUROBINDO PHARMA USA
24.1.17.1. COMPANY OVERVIEW
24.1.17.2. REVENUE ANALYSIS
24.1.17.3. GEOGRAPHIC PRESENCE
24.1.17.4. PRODUCT PORTFOLIO
24.1.17.5. RECENT DEVELOPMENTS
24.2 PIPELINE MANUFACTURE
24.2.1 REGENINNOPHARM INC.
24.2.1.1. COMPANY OVERVIEW
24.2.1.2. REVENUE ANALYSIS
24.2.1.3. GEOGRAPHIC PRESENCE
24.2.1.4. PRODUCT PORTFOLIO
24.2.1.5. RECENT DEVELOPMENTS
24.2.2 CELECOR THERAPEUTICS
24.2.2.1. COMPANY OVERVIEW
24.2.2.2. REVENUE ANALYSIS
24.2.2.3. GEOGRAPHIC PRESENCE
24.2.2.4. PRODUCT PORTFOLIO
24.2.2.5. RECENT DEVELOPMENTS
24.2.3 IDORSIA PHARMACEUTICALS LTD
24.2.3.1. COMPANY OVERVIEW
24.2.3.2. REVENUE ANALYSIS
24.2.3.3. GEOGRAPHIC PRESENCE
24.2.3.4. PRODUCT PORTFOLIO
24.2.3.5. RECENT DEVELOPMENTS
24.2.4 KANCERA AB.
24.2.4.1. COMPANY OVERVIEW
24.2.4.2. REVENUE ANALYSIS
24.2.4.3. GEOGRAPHIC PRESENCE
24.2.4.4. PRODUCT PORTFOLIO
24.2.4.5. RECENT DEVELOPMENTS
24.2.5 TWBIO-THERA.COM
24.2.5.1. COMPANY OVERVIEW
24.2.5.2. REVENUE ANALYSIS
24.2.5.3. GEOGRAPHIC PRESENCE
24.2.5.4. PRODUCT PORTFOLIO
24.2.5.5. RECENT DEVELOPMENTS
24.2.6 MESOBLAST LTD
24.2.6.1. COMPANY OVERVIEW
24.2.6.2. REVENUE ANALYSIS
24.2.6.3. GEOGRAPHIC PRESENCE
24.2.6.4. PRODUCT PORTFOLIO
24.2.6.5. RECENT DEVELOPMENTS
24.2.7 FARADAY PHARMACEUTICALS
24.2.7.1. COMPANY OVERVIEW
24.2.7.2. REVENUE ANALYSIS
24.2.7.3. GEOGRAPHIC PRESENCE
24.2.7.4. PRODUCT PORTFOLIO
24.2.7.5. RECENT DEVELOPMENTS
24.2.8 RESOTHER PHARMA
24.2.8.1. COMPANY OVERVIEW
24.2.8.2. REVENUE ANALYSIS
24.2.8.3. GEOGRAPHIC PRESENCE
24.2.8.4. PRODUCT PORTFOLIO
24.2.8.5. RECENT DEVELOPMENTS
24.2.9 ACTICOR BIOTECH SA
24.2.9.1. COMPANY OVERVIEW
24.2.9.2. REVENUE ANALYSIS
24.2.9.3. GEOGRAPHIC PRESENCE
24.2.9.4. PRODUCT PORTFOLIO
24.2.9.5. RECENT DEVELOPMENTS
24.2.10 NOVO NORDISK
24.2.10.1. COMPANY OVERVIEW
24.2.10.2. REVENUE ANALYSIS
24.2.10.3. GEOGRAPHIC PRESENCE
24.2.10.4. PRODUCT PORTFOLIO
24.2.10.5. RECENT DEVELOPMENTS
25 CONCLUSION
26 QUESTIONNAIRE
27 ABOUT DATA BRIDGE MARKET RESEARCH
